What Septerna, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 15 | 40 |
| Total trades | 18 | 62 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 25,833 | 328,314 |
| Disposed | 107,653 | 1,755,934 |
| Net activity | −81,820 | −1,427,620 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Finer Jeffrey | Chief Executive Officer | Nov 12 | Open-market sale · S | −1,977 | $46.16 | −$91.3K | 833,909 |
| Finer Jeffrey | Chief Executive Officer | Nov 12 | Open-market sale · S | −2,823 | $45.28 | −$128K | 835,886 |
| Finer Jeffrey | Chief Executive Officer | Nov 12 | Open-market sale · S | −2,800 | $44.23 | −$124K | 838,709 |
| Finer Jeffrey | Chief Executive Officer | Nov 12 | Open-market sale · S | −5,300 | $43.10 | −$228K | 841,509 |
| Finer Jeffrey | Chief Executive Officer | Nov 12 | Open-market sale · S | −5,600 | $42.09 | −$236K | 846,809 |
| Finer Jeffrey | Chief Executive Officer | Nov 12 | Exercise / conversion · M | +18,500 | $2.76 | +$51.1K | 852,409 |
| Ezekowitz Alan | Director | Nov 11 | Open-market sale · S | −1,055 | $51.90 | −$54.8K | 35,600 |
| Ezekowitz Alan | Director | Nov 11 | Open-market sale · S | −2,013 | $50.90 | −$102K | 36,655 |
| Ezekowitz Alan | Director | Nov 11 | Open-market sale · S | −4,175 | $49.65 | −$207K | 38,668 |
| Ezekowitz Alan | Director | Nov 11 | Open-market sale · S | −31,572 | $48.70 | −$1.54M | 42,843 |
| Ezekowitz Alan | Director | Nov 11 | Open-market sale · S | −22,865 | $47.78 | −$1.09M | 74,415 |
| Ezekowitz Alan | Director | Nov 11 | Open-market sale · S | −13,201 | $47.01 | −$621K | 97,280 |
| Ezekowitz Alan | Director | Nov 11 | Open-market sale · S | −6,939 | $46.01 | −$319K | 110,481 |
| Bhatt Elizabeth | President and COO | Oct 15 | Open-market sale · S | −2,906 | $37.61 | −$109K | 174,209 |
| Bhatt Elizabeth | President and COO | Oct 15 | Open-market sale · S | −1,094 | $36.87 | −$40.3K | 177,115 |
| Bhatt Elizabeth | President and COO | Oct 15 | Exercise / conversion · M | +4,000 | $6.81 | +$27.2K | 178,209 |
| Long Daniel D. | SVP, Drug Discovery | Sep 01 | Open-market sale · S | −3,333 | $37.83 | −$126K | 96,412 |
| Long Daniel D. | SVP, Drug Discovery | Sep 01 | Exercise / conversion · M | +3,333 | $2.76 | +$9.2K | 99,745 |
| Third Rock Ventures V, L.p. | 10% owner | Aug 12 | Open-market sale · S | +141 | $51.08 | +$7.2K | 6,068,391 |
| Ra Capital MANAGEMENT, L.p. | Director | Aug 12 | Open-market sale · S | −746,500 | $42.50 | −$31.7M | 725,443 |
Loading...